2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1499

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Abstract Number: 1500

Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Abstract Number: 1501

Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Abstract Number: 1502

The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Abstract Number: 1503

Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Abstract Number: 1504

Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Abstract Number: 1505

Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Abstract Number: 1506

Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results
Abstract Number: 1507

Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1508

Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Abstract Number: 1509

Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Abstract Number: 1510

Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1511

Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Abstract Number: 1512

Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results
Abstract Number: 1513

Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].